### Analysis

The earnings call for Amgen Inc. provided a mixed picture of the company's performance and future prospects. Key points include:

1. **Financial Results**: Amgen reported a 1% increase in global product sales, with anemia franchise sales declining 16% and other products increasing 17%. Operating expenses decreased by 1% year-over-year, driven by cost-cutting efforts.

2. **Pipeline and Regulatory**: Amgen highlighted progress in its pipeline, including new data for Vectibix and denosumab. The company is also working on regulatory updates for ESA labeling and is optimistic about the future of its products.

3. **Restructuring**: The company continues to make progress on its restructuring program, aiming to achieve $600 million to $800 million in pre-tax savings and reduce headcounts by 12% to 14%.

4. **Market Uncertainty**: Despite the progress, Amgen faces uncertainty in the market, particularly around Aranesp and ENBREL, due to regulatory changes and competition.

### Conclusion

The stock is likely to face short-term pressure due to tempered guidance and uncertainties around key defense contracts. The company's focus on cost-cutting and strategic growth suggests long-term potential, but the near-term outlook is likely to be challenging.

### Rating

-1